证券代码：301258 证券简称：富士莱 公告编号：2023-056 苏州富士莱医药股份有限公司 关于使用部分闲置自有资金进行委托理财的进展公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）于 2023 年 3 月 14 日召开 第四届董事会第四次会议、第四届监事会第四次会议以及 2023 年 3 月 31 日召开 2023 年第一次临时股东大会，审议通过了《关于使用部分闲置自有资金进行委 托理财的议案》，为提高资金使用效率，在不影响公司正常经营的情况下，同意 公司使用不超过 120,000.00 万元闲置自有资金进行中低风险投资理财。具体内容 详见公司 2023 年 3 月 15 日和 2023 年 3 月 31 日披露于巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 近期，公司使用部分闲置自有资金进行了委托理财，现将有关情况进展公告 如下： | 序 | 受托方名称 | 产品名称 | 金额（万 | 产品类型 | 产品起息日 | 产品到期日 | 预期年化收益 | | --- | - ...

证券代码：301258 证券简称：富士莱 公告编号：2023-055 苏州富士莱医药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公 告 | 序 | 受托方名称 | 产品名称 | 金额（万 | 产品类型 | 产品起息 | 产品到期 | 预期年化收益 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | 元） | | 日 | 日 | 率 | | 1 | 苏州银行股 份有限公司 | 2023 年第 2112 期标准化结构性 | 14,000.00 | 保本浮动 收益型产 | 2023-11-6 | 2023-12-9 | 1.7%或 2.5%或 | | | 常熟支行 | 存款 | | 品 | | | 2.6% | 一、本次募集资金现金管理的基本情况 二、关联关系 公司与上述受托方不存在关联关系，本次使用部分闲置募集资金进行现金管 理不会构成关联交易。 三、投资风险及风险控制措施 （一）投资风险 1、尽管公司拟选择的投资产品属于低风险投资品种，但金融市场受宏观经 济的影响较大。 2、公司将根据经济形势以及金融市场的变化适时适量的介入，但 ...

苏州富士莱医药股份有限公司 2023 年第三季度报告 证券代码：301258 证券简称：富士莱 公告编号：2023-054 苏州富士莱医药股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 （二） 非经常性损益项目和金额 适用 □不适用 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 苏州富士莱医药股份有限公司 2023 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 9 ...

Group 1: Financial Performance - The company reported a net profit decline of 23.67% year-on-year for Q2 2023, primarily due to exchange gains and investment income impacts [3] - As of June 30, 2023, the company had total orders amounting to 88.12 million yuan, representing all product orders [4] - The total number of shareholders as of August 18, 2023, was 13,229 [3] Group 2: Stock and Market Strategy - The company is considering stock repurchase measures to boost stock prices, which have been below the issue price since listing [2] - The company plans to explore CMO/CDMO business opportunities and seek collaborations with other domestic pharmaceutical companies [5] - The company is actively looking for acquisition targets to enhance competitiveness and achieve resource integration [5] Group 3: Product and Market Development - The company has invested in a subsidiary focused on medical devices and cosmetics, indicating a strategic shift towards the medical beauty sector [4] - The company’s core products, including lipoic acid and phosphatidylcholine, remain central to revenue and profit, with plans to optimize production processes [5] - The company is facing challenges in export orders due to external demand fluctuations and is actively seeking new orders [4] Group 4: Risk Management and Future Outlook - The company acknowledges potential risks from market fluctuations and plans to adjust product pricing to maintain market share [6] - The company is committed to enhancing its R&D capabilities and exploring innovative solutions to remain competitive [6] - The company’s pricing strategy is not solely cost-plus, but considers market demand, inventory, and competitor pricing [6]

苏州富士莱医药股份有限公司 2023 年半年度报告全文 苏州富士莱医药股份有限公司 2 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人钱祥云、主管会计工作负责人卞爱进及会计机构负责人(会计 主管人员)卞爱进声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应 对措施"部分，详细描述了公司经营中可能存在的风险及应对措施，敬请投资 者关注相关内容。 2023 年半年度报告 2023 年 8 月 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 苏州富士莱医药股份有限公司 2023 年半年度报告全文 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 6 | | 第三节 | 管理层讨论与分析 | 9 | | 第四节 | 公司治理 | 24 | | 第五节 | 环境 ...

苏州富士莱医药股份有限公司 2023 年第一季度报告 证券代码：301258 证券简称：富士莱 公告编号：2023-026 苏州富士莱医药股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第一季度报告是否经过审计 □是 否 1 苏州富士莱医药股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 156,494,544.37 | 141,779,121.55 | | 10.38 ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-on-year growth of 15%[12] - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[12] - The company's operating revenue for 2022 was ¥568,213,343.96, an increase of 8.92% compared to ¥521,695,665.95 in 2021[17] - The net profit attributable to shareholders for 2022 was ¥177,303,662.82, representing a significant increase of 47.51% from ¥120,201,415.72 in 2021[17] - The net profit after deducting non-recurring gains and losses was ¥172,416,638.82, up 49.39% from ¥115,415,204.48 in the previous year[17] - The total assets at the end of 2022 reached ¥2,098,360,763.12, a substantial increase of 116.26% from ¥970,306,076.54 at the end of 2021[17] - The net assets attributable to shareholders increased by 153.97% to ¥1,886,610,054.50 from ¥742,839,394.81 in 2021[17] - The basic earnings per share for 2022 were ¥2.06, reflecting a growth of 17.71% compared to ¥1.75 in 2021[17] - The weighted average return on equity decreased to 11.33% in 2022 from 17.61% in 2021, a decline of 6.28%[17] - The net cash flow from operating activities was ¥151,187,132.90, down 24.30% from ¥199,729,417.14 in 2021[17] Dividend Distribution - The company plans to distribute a cash dividend of 5.80 RMB per 10 shares, totaling approximately 53 million RMB[3] - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 36,668,000.00 RMB, based on a total share capital of 91,670,000 shares[130] - The total cash dividend represents 100% of the distributable profit of 604,523,135.61 RMB[133] - No new shares will be issued as part of the dividend distribution, and no capital reserve will be converted into share capital[133] Market Expansion and Strategy - The company has set a revenue target of 1.5 billion RMB for 2023, indicating a growth forecast of 25%[12] - User data showed an increase in active users by 25% year-on-year, reaching 500,000 active users by the end of 2022[12] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[12] - A strategic acquisition of a local biotech firm was completed, enhancing the company's R&D capabilities and product pipeline[12] - The company aims to expand into the CMO/CDMO sectors, providing contract manufacturing and development services to pharmaceutical companies[34] Research and Development - New product development includes the launch of three innovative drugs expected to enter the market in 2023, with projected sales of 300 million RMB[12] - The company holds 41 patents, including 40 invention patents, demonstrating its strong R&D capabilities and innovation[36] - R&D expenses for the year were 41.37 million yuan, a 45.08% increase year-on-year, representing 7.28% of total revenue, marking a historical high for R&D investment intensity[52] - The number of R&D personnel increased by 34.18% to 106 in 2022, with a higher proportion of personnel holding bachelor's degrees (54%)[66] Environmental Compliance - The company has received environmental impact assessment approvals for multiple projects, including a major project for the construction of a research and development center approved on November 21, 2022[141] - The valid pollutant discharge permit issued on December 29, 2021, allows the company to emit volatile organic compounds, particulate matter, sulfur dioxide, nitrogen oxides, toluene, benzene, hydrochloric acid, ammonia, and other pollutants until December 28, 2026[141] - The company has successfully completed environmental protection acceptance for various projects, including the expansion project for the production of 720 tons of pharmaceutical intermediates and raw materials[140] - The company has undergone multiple environmental assessments and approvals since 2010, demonstrating compliance with environmental regulations and standards[140] - The company has a comprehensive environmental management strategy in place, focusing on reducing emissions and optimizing production processes[140] Corporate Governance - The company maintains a complete and independent business system, ensuring no asset or fund occupation by controlling shareholders[104] - The company has established a comprehensive personnel management system, ensuring independence from controlling shareholders in management roles[104] - The company’s governance structure complies with relevant laws and regulations, ensuring orderly management and operation[103] - The company has developed a robust procurement, production, and sales system, maintaining full control over its assets[104] - The company has a clear internal management and control system, tailored to its operational needs[105] Financial Management - The company has a rigorous fundraising management system in place to ensure that raised funds are used effectively for designated projects[175] - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[178] - The company has committed to compensating investors for losses incurred due to fraudulent issuance if such a situation arises[175] - The company has outlined measures to enhance corporate governance and protect the rights of minority shareholders[175] Social Responsibility - The company donated CNY 200,000 to the Changshu Charity Federation and contributed CNY 100,000 to the Nanjing Medical University Education Development Foundation during the reporting period[155] - The company has actively engaged in social responsibility initiatives, including employment support for five disabled individuals[155] Challenges and Risks - The company has faced challenges due to global supply chain disruptions and rising commodity prices, which have affected production and operational costs[45] - Risk management strategies have been outlined to address potential regulatory changes and market volatility, ensuring business continuity[3] Production and Capacity - The company plans to expand its production capacity through fundraising projects, aiming to overcome current capacity bottlenecks and increase market share[42] - The production capacity utilization rate for the alpha-lipoic acid series was 105.24%, indicating strong demand and efficient production[48] - The sales revenue from the alpha-lipoic acid series reached 453.76 million yuan, a year-on-year increase of 10.10%, contributing 79.86% to the main business revenue[54] Investor Relations - The company held a total of 54 investor communication meetings in August 2022, including a conference call on August 23, 2022[100] - The company has been actively engaging with various institutional investors to enhance transparency and communication[100] - The company held multiple shareholder meetings in 2022, with investor participation rates of 75.09%, 74.89%, 65.67%, and 64.06% for the respective meetings[106]

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220712 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | 参与单位名称及 人员姓名 | 中泰证券 李建 | | | 时间 | 2022 年 07 月 12 | 日（周二） 15:30-16:00 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | ...

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220726 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | √特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n □业绩说明会 \n □路演活动 \n □其他 | | 参与单位名称及 人员姓名 | ...